- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01200563
Comparative Effectiveness Study of MIST Therapy Versus Negative Pressure Wound Therapy
Comparative, Prospective, Randomized Study of MIST Therapy vs NPWT vs MIST Therapy in Conjunction With NPWT on the Rate of Healing and Its Economic Value in the Treatment of Full Thickness Wounds in a LTACH and SNF
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A comparative, prospective, randomized study.
Study objectives: Comparison between study groups of the assigned study treatment's effect on the rate of wound healing, cost per episode of care, severity of wound pain, and the occurrence of adverse events.
Subject recruitment: Consecutive, prospective subjects admitted to the study site will be screened for study enrollment and potential randomization. Prospective data will be collected on study subjects until at least 10 subjects are randomized into each of three treatment groups: MIST Therapy; NPWT; or MIST Therapy and NPWT.
Protocol and procedures: All randomized subjects will continue to receive standard of care treatment appropriate for their wound for the duration of their study treatment regardless of their assigned treatment group. Subjects will continue to receive assigned study treatment as long as their wound continues to show improvement, as determined by the investigator. Study treatment will continue until wound closure, or for up to 6 weeks without wound closure. A baseline evaluation will include a medical history assessment, VAS pain score, wound history and evaluation including: wound dimension measurements, overall wound assessment, digital photography, and appropriate sharp debridement, if necessary. Weekly wound assessments will include a wound evaluation, digital photography and VAS pain score. Prospective data will also be collected on specific wound care supplies and interventions provided. These data will be tracked as interventions occur while the wound continues to be treated with the assigned study treatment. Economic data will include type, quantity, duration, associated frequency, and professional time requirements.
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Arizona
-
Mesa, Arizona, United States, 85206
- Trillium Specialty Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subject of any race and at least 18 years old
- Subject presents with full thickness wound of any etiology
- Subject's wound is between 20cm2 and 250cm2
- Subject's wound has less that 20% necrotic tissue
- Subject is nutritionally stable and/or taking nutritional supplements and is being followed by a dietician
- Subject or subject's legally authorized representative understands the nature of the study procedure(s) and provides written informed consent prior to study enrollment
- Women of childbearing potential must not be pregnant or lactating, and must be using adequate and accepted contraceptive methods
- Subject has a reasonable expectation of completing the study
- Subject has had no prior MIST Therapy or Negative Pressure Wound Therapy to the enrolled wound
Exclusion Criteria:
- Subject's condition requires the use of topical antibiotics at the time of study enrollment
- Subject's wound would require ultrasound near an electronic implant or prosthesis, e.g., near or over the heart, or over the thoracic area if the patient is using a cardiac pacemaker
- Subject is known to be suffering from a disorder or other situation that the subject or investigator feels would interfere with compliance or other study requirements
- Subject is currently enrolled or has been enrolled in the last 30 days in another investigational device or drug trial
- Subject has a combination of medical condition(s) that in the opinion of the investigator would make the subject an inappropriate candidate for the study, i.e., diabetes, including renal, hepatic, hematologic, neurologic, or immune disease
- Subject's wound is not appropriate for Negative Pressure Wound Therapy or MIST Therapy
- Subject has osteomyelitis, systemic sepsis, or an infection not related to his/her index wound (e.g., UTI, pulmonary) that has been untreated or has not been appropriately managed
- Subject has a fistula(s) to the index wound bed
- Subject's index wound is a head or neck wound
- Subject's index wound presents with a malignancy in the wound bed
- Subject's anticoagulation therapy is unstable
- Subject is undergoing chemotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group 1
Subjects assigned to receive MIST Therapy will be treated 3 times per week.
The duration of each MIST treatment will be dependent on the wound's area measured at baseline and at each weekly assessment.
|
Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
Other Names:
|
Active Comparator: Group 2
Subjects assigned to receive Negative Pressure Wound Therapy will be treated with the Vacuum Assisted Closure system.
For administration of this study treatment, e.g., treatment cycle, target pressure and dressing changes, the manufacturer's recommended guidelines will be followed.
|
Controlled negative pressure (vacuum) delivering negative (sub-atmospheric) pressure to the wound site applied by a tubing which decompresses a foam dressing, continuously or intermittently depending on wound type.
Other Names:
|
Active Comparator: Group 3
Subjects assigned to this group will receive MIST Therapy treatments and Negative Pressure Wound Therapy.
|
MIST Therapy will be provided 3 times per week, NPWT will be provided according to the manufacturer's recommended guidelines.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of wound healing.
Time Frame: 6 weeks
|
Determined by the change in wound surface area/volume from the initial evaluation date to study end.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change wound exudation levels.
Time Frame: 6 weeks
|
Determined by the change in amount of exudates recorded using a scale of none, mild, moderate, and heavy, from the initial evaluation date to study end.
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kenneth O Anaeme, MD, Trillium Specialty Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR-86000
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wounds
-
Centre Hospitalier Universitaire de NīmesCompleted
-
3MWithdrawn
-
University of WashingtonU.S. Department of Justice; Arnold Ventures; City of SeattleCompleted
-
Smith & Nephew, Inc.Not yet recruitingChronic Wounds | Acute WoundsCanada
-
SerenaGroup, Inc.MDM Wound Ventures, LLCCompletedChronic Wounds | Acute WoundsUnited States
-
Hospital Universiti Sains MalaysiaActive, not recruiting
-
Ohio State UniversityCompleted
-
University of PittsburghThe Pittsburgh Foundation; Hillman Foundation; RK Mellon FoundationCompletedSkin Injury Due to Violence | Gunshot Wound, ContactUnited States
-
SerenaGroup, Inc.Anacapa Technologies IncCompleted
-
Medical University of South CarolinaCompletedNeedlestick InjuriesUnited States
Clinical Trials on MIST Therapy
-
Celleration, Inc.TerminatedWound of SkinUnited States
-
Celleration, Inc.CompletedCosmetic SurgeryUnited States
-
Celleration, Inc.Completed
-
Celleration, Inc.CompletedVenous Insufficiency | Venous Reflux | Lower Extremity UlcerUnited States
-
Cardiff and Vale University Health BoardCelleration, Inc.CompletedVaricose UlcerUnited Kingdom
-
National University Hospital, SingaporeCompleted
-
McGuire InstituteBiolase IncCompletedPeriodontal DiseasesUnited States
-
Celleration, Inc.TerminatedDiabetic Foot UlcerUnited States
-
Texas Health ResourcesCelleration, Inc.CompletedChronic Ulcer of Lower ExtremityUnited States
-
University of WashingtonNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHIV PreventionUnited States